Diagnostic and statistical manual of mental disorders (DSM-IV). Washington (DC): American Psychiatric Association; 1994. p 452–7.
2.
KaplanHSadockBGrebbJ. Synopsis of psychiatry. 7th ed.Baltimore (MD): Williams and Wilkins; 1994. p 621–4.
3.
SrinathSBharatSGirimajiSSeshardiS. Characteristics of child inpatient population with hysteria in India. J Am Acad Child Adolesc Psychiatry1993;32:822–5.
4.
GarraldaME. A selective review of child psychiatric syndromes with a somatic presentation. Br J Psychiatry1992;161:759–73.
5.
DulaDJDeNaplesL. Emergency department presentation of patients with conversion disorder. Acad Emerg Med1995;2:120–3.
6.
QuaneTChamberCVShydermanD. Conversion disorder presenting as gait disturbance in an adolescent. Arch Fam Med1995;4:805–7.
ChouinardGRoss-ChouinardAAnnableLJonesBDW. The extrapyramidal symptom rating scale. Can J Neurol Sci1980;7:233.
9.
BeckAT. Beck depression inventory manual. San Antonio (TX): Psychological Corporation; 1987.
10.
FischerVVogelsBMaurerGTynesR. The antipsychotic clozapine is metabolized by the polymorphic human microsomal and recombinant cytochrome P450 2D6. J Pharmacol Exp Ther1992;260:1355–60.
11.
CentorrinoFBaldessariniRKandoJFrankenburgFRVolpicelliSAFloodJG. Clozapine and metabolites: Concentrations in serum and clinical findings during treatment of chronically psychotic patients. J Clin Psychopharmacol1994;14:119–25.
12.
CentorrinoFBaldessariniRKandoJFrankenburgFRVolpicelliSA, Puopolo PR, and others. Serum concentrations of clozapine and its major metabolites: Effects of cotreatment with fluoxetine or valproate. Am J Psychiatry1994;151:123–5.
13.
KingsburySPuckettK. Effects of fluoxetine on serum clozapine levels. Am J Psychiatry1995;152:473–4.
14.
MorseR. Clozapine threshold plasma concentrations and drug interactions affecting clozapine concentrations. Riverview Hospital Pharmacy Newsletter1996;16:1.
15.
HymanSETesarGE. Manual of psychiatric emergencies. 3rd ed. Boston (MA): Little; 1994. p 205–6.
16.
GelderMGathDMayouRDowenP. Oxford textbook of psychiatry. 3rd ed. New York: Oxford University Press; 1996. p 552.
17.
ChilesJA. Extrapyramidal reactions in adolescents treated with high potency antipsychotics. Am J Psychiatry1978;135:239–40.
18.
RussellAT. In: GabbardG, editor. Childhood onset schizophrenia in treatment of psychiatric disorders. 2nd ed.Washington (DC): American Psychiatric Association; 1995. p 329–34.
19.
KhannaRDasADamodavanS. Prospective study of neuroleptic-induced mania and schizophrenia. Am J Psychiatry1992;149:511–3.
20.
KaplanHSadockB. Comprehensive textbook of psychiatry. 6th ed. Baltimore (MD): Williams and Wilkins; 1995. p 1911–12.
21.
O'MalleySSJaffeAJChangGSchottenfieldRSMeyerRERounsavilleB. Naltrexone and coping skills therapy for alcohol dependence. Arch Gen Psychiatry1992;49:881–7.
22.
O'MalleySSJaffeAJChangGRodeSSchottenfieldRS, Meyer RE, and others. Six-month follow-up of naltrexone and psychotherapy for alcohol dependence. Arch Gen Psychiatry1996;53:217–4.
23.
VolpicelliJR. Naltrexone in alcohol dependence [letter]. Lancet1995;346:456.
24.
O'MalleySSJaffeAJRodeSRounsavilleBJ. Experience of a “slip” among alcoholics treated with naltrexone or placebo. Am J Psychiatry1996;153:281–3.
25.
VolpicelliJRWatsonNTKingACShermanCEO'BrienCP. Effect of naltrexone on alcohol “high” in alcoholics. Am J Psychiatry1995;152:613–5.
26.
CrockfordDNel-GuebalyN. Psychiatric comorbidity in pathological gambling: A critical review. Can J Psychiatry. Forthcoming.
27.
CastellaniBRugleL. A comparison of pathological gamblers to alcoholics and cocaine misusers on impulsivity, sensation seeking, and craving. Int J Addict1995;30:275–89.
28.
LesieurHRBlumeSB. The South Oaks gambling screen (SOGS): A new instrument for the identification of pathological gamblers. Am J Psychiatry1987;144:1184–8.
29.
AntonRFMoakDHLathamPK. The obsessive compulsive drinking scale: A new method of assessing outcome in alcoholism treatment studies. Arch Gen Psychiatry1996;53:225–31.
30.
Perez-CruetJF. Immediate naltrexone decreases in alcoholic intake urges as predictor of a good outcome [abstract]. In: American Psychiatric Association annual meeting program; 1997 May 17–22; San Diego. Washington (DC): American Psychiatric Association; 1997.